Concord Biosciences Holdings, Inc. (HRMY) Presents at forty fourth Annual J.P. Morgan Healthcare Convention Transcript

Sherry Yang

Hello, everybody, and welcome once more to the forty fourth JPM Healthcare Convention. I’m Sherry Yang, an Affiliate from the Healthcare Funding Banking Group, and it is a pleasure to be introducing Concord Biosciences.

In the present day, we’ve got Jeff Dayno, President and CEO on stage with me for the presentation and Sandip Kapadia, CFO. Kumar Budur, Chief Medical and Scientific Officer; and Adam Zaeske, Government VP and Chief Business Officer within the viewers. Please be a part of me in welcoming Jeff to the rostrum. Thanks.

Jeffrey Dayno
President, CEO & Director

Thanks, Sherry. Good afternoon, everybody. And on behalf of the Concord group, I need to thank JPMorgan for the invitation to current once more at this yr’s convention. I am actually excited to be right here with all of you to share Concord’s outlook, a really nice outlook for 2026.

Our forward-looking assertion, please consult with our web site for our newest SEC filings. The theme is momentum. Concord enters 2026 with vital momentum and propelled by 3 key drivers. First WAKIX efficiency with 5 years of consecutive development and profitability, our 2026 steerage factors to over $1 billion in web income, which implies that WAKIX is on observe to attain blockbuster standing this yr.

Driver #2, a sturdy late-stage pipeline. With 5 Section III packages within the clinic advancing in direction of 5 distinct CNS indications, which can set us up for a number of catalysts over the subsequent few years. And the third driver, our sturdy monetary profile. Concord is a worthwhile